FDA gives tentative approval to Teva's generic Valtrex
JERUSALEM Teva has received tentative approval from the Food and Drug Administration to market a generic version of GlaxoSmithKline’s herpes drug Valtrex, according to the Associated Press.
Final approval on the generic will be expected in December 2009 after the patent expires on the brand. Mylan has also received tentative approval for a generic version of Valtrex as well.
Valtrex had sales of about $1.3 billion last year.